Drug Trial Radar · NCT07229612
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Dec 3, 2025
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.
Conditions
- Malignant Solid Tumors
Interventions
SHR-4298 InjectionDrug
SHR-4298 injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs).Time frame: Approximately 18 months.
- Incidence and severity of serious adverse events (SAEs).Time frame: Approximately 18 months.
- Maximum Tolerated Dose (MTD).Time frame: Approximately 18 months.
- Maximum Applicable Dose (MAD).Time frame: Approximately 18 months.
- Recommended Phase 2 Dose (RP2D).Time frame: Approximately 18 months.
- Dose-limiting toxicity (DLT).Time frame: Approximately 18 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.